Phosphate Control: The Next Frontier in Dialysis Cardiovascular Mortality

Area of Science:

• Nephrology
• Cardiology
• Pharmacology

Background:

• Cardiovascular disease (CVD) is a leading cause of death in chronic kidney disease (CKD) patients undergoing dialysis.
• Hyperphosphatemia, common in advanced CKD, significantly contributes to this elevated mortality risk.
• Phosphate retention triggers detrimental physiological pathways, including elevated FGF23 and PTH, exacerbating CVD risk.

Purpose of the Study:

• To highlight the challenges in managing hyperphosphatemia in dialysis patients.
• To underscore the inadequacy of current phosphate control strategies.
• To introduce the potential of novel therapies targeting the intestinal paracellular pathway for phosphate absorption.

Main Methods:

• Review of existing literature on hyperphosphatemia management in CKD.
• Analysis of the limitations of dietary phosphate restriction, dialysis, and current phosphate binders.
• Exploration of emerging therapeutic strategies focusing on the paracellular absorption pathway.

Main Results:

• Current management approaches, including dietary changes, dialysis, and phosphate binders, frequently fail to achieve target phosphate levels (<5.5 mg/dL).
• Phosphate binders have limited efficacy due to non-specific binding and inability to target the primary absorption pathway.
• A significant unmet need exists for more effective hyperphosphatemia treatments in dialysis patients.

Conclusions:

• Despite established guidelines, achieving and maintaining target phosphate levels remains a significant challenge for most dialysis patients.
• The limitations of current therapies necessitate the development of innovative treatments.
• Targeting the intestinal paracellular phosphate absorption pathway presents a promising strategy for improved phosphate control and reduced CVD risk.